PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression - Jiao, Shiping; Xia, Weiya; Yamaguchi, Hirohito; Wei, Yongkun; Chen, Mei-Kuang; Hsu, Jung-Mao; Hsu, Jennifer L.; Yu, Wen-Hsuan; Du, Yi; Lee, Heng-Huan; Li, Chia-Wei; Chou, Chao-Kai; et al. (Clinical cancer research, 2017)
Keywords: Animal models; Animals; Anticancer properties; B7-H1 Antigen - genetics; B7-H1 Antigen - immunology; Biotechnology; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - immunology; Breast Neoplasms - pathology; Cancer; Cell culture; Cell Line, Tumor; Experimental design; Female; Flow cytometry; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immune checkpoint; Immunity; Immunoblotting; Immunosuppression; In vivo methods and tests; Inhibitors; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - immunology; Mice; PD-1 protein; PD-L1 protein; Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors; Poly (ADP-Ribose) Polymerase-1 - immunology; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage; Poly(ADP-ribose) Polymerase Inhibitors - immunology; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - immunology; Tumor cell lines; Tumor cells; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; Tumor suppression; Tumor-infiltrating lymphocytes; Tumors; Xenograft Model Antitumor Assays; Xenografts